S Alireza Rabi

S Alireza Rabi

Auto-generated profile, based on publicly available information

S Alireza Rabi

Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2011 in Retrovirology
Verified
Journal Article
Open access
PDF file
MSMaria Salgado
Maria Salgado
SRS Alireza Rabi
S Alireza Rabi
KOKaren A O'Connell
Karen A O'Connell
RIRobert W Buckheit Iii
Robert W Buckheit Iii
JBJustin R Bailey
Justin R Bailey
JBJoel Blankson
Joel Blankson
Background: While initiation of highly active antiretroviral therapy (HAART) during primary HIV-1 infection occasionally results in transient control of viral replication after treatment interruption, the vast majority of patients eventually experience a rebound in plasma viremia.Results: Here we report a case of a patient who was started on HAART during symptomatic primary infection and who has subsequently maintained viral loads of < 50 copies/mL for more than nine years after the cessation of treatment. This patient had a high baseline viral load and has maintained a relatively high frequency of latently infected CD4+T cells. In addition, he does not have any known protective HLA alleles. Thus it is unlikely that he was destined to become a natural elite controller or suppressor. The mechanism of control of viral replication is unclear; he is infected with a CCR5/CXCR4 dual-tropic virus that is fully replication-competentin vitro. In addition, his spouse, who transmitted the virus to him, developed AIDS. The patient's CD4+T cells are fully susceptible to HIV-1 infection, and he has low titers of neutralizing antibodies to heterologous and autologous HIV-1 isolates. Furthermore, his CD8+T cells do not have potent HIV suppressive activity.Conclusion: This report suggests that some patients may be capable of controlling pathogenic HIV-1 isolates for extended periods of time after the cessation of HAART through a mechanism that is distinct from the potent cytotoxic T lymphocyte (CTL) mediated suppression that has been reported in many elite suppressors.